Aligos Therapeutics, Inc. Proceeds from Stock Options Exercised
Aligos Therapeutics, Inc. (ALGS) reported Proceeds from Stock Options Exercised of $23.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-11-06
- Aligos Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2023-03-31 was $23.00K, a 130.00% increase year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2022-09-30 was $9.00K, a 50.00% decline year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock options exercised for fiscal 2020 was $260.00K, a 46.61% decline from fiscal 2019.
- Aligos Therapeutics, Inc. proceeds from stock options exercised for fiscal 2019 was $487.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $23.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $23.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $23.00K 10-Q · filed 2024-05-07 | |||
| 2022-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $10.00K derived: sum of 2 quarters · filed 2023-11-02 | $20.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $11.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $231.00K derived: sum of 2 quarters · filed 2022-11-02 | $327.00K 10-Q · filed 2022-11-02 | $390.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $309.00K 10-Q · filed 2022-08-04 | $372.00K derived: sum of 3 quarters · filed 2022-08-04 | $507.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $96.00K 10-Q · filed 2022-05-04 | $159.00K derived: sum of 2 quarters · filed 2022-05-04 | $294.00K derived: sum of 3 quarters · filed 2022-05-04 | $338.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $198.00K derived: sum of 2 quarters · filed 2021-11-04 | $242.00K derived: sum of 3 quarters · filed 2021-11-04 | $260.00K 10-K · filed 2021-03-23 |
| 2020-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $179.00K derived: sum of 2 quarters · filed 2021-11-04 | $197.00K 10-Q · filed 2021-11-04 | $389.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $62.00K 10-Q · filed 2021-08-05 | $254.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $18.00K 10-Q · filed 2021-05-10 | $210.00K derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $487.00K 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $295.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |